Investor Relations

Mr. Wood has served as our President and Chief Executive Officer since September 2025 and a member of our board of directors since April 2024. He previously served as Corporate Vice President, Transcatheter Aortic Valve Replacement from February 2007 to September 2025, and as Group President for Surgical Structural Heart from 2023 to September 2025, at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Mr. Wood has more than 35 years of experience in the medical technology industry at both Edwards Lifesciences and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School.

Mr. Waters has served as our EVP, Chief Financial Officer since January 2022. He previously served as our SVP, Chief Financial Officer from October 2018 until December 2021. Prior to joining PROCEPT BioRobotics Mr. Waters served as Chief Financial Officer at Accuray Inc., a radiation oncology company, from September 2015 to October 2018. In addition to his experience at Accuray, Inc., Mr. Waters held financial leadership positions at three publicly traded medical device companies, including Conceptus, Laserscope and VISX. These companies were all sold to strategic acquirers, generating approximately $3 billion in shareholder value. Mr. Waters began his career at PricewaterhouseCoopers, LLP. and received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.

Ms. Nouri has served as our EVP, Chief Legal Officer & Corporate Secretary since January 2022. She has also served as our Chief Compliance Officer since September 2018. She previously served as our SVP, General Counsel & Corporate Secretary from July 2018 until December 2021. Prior to joining PROCEPT BioRobotics, Ms. Nouri served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Inc., a radiation oncology company, from February 2014 to July 2018. In her more than 15-year legal career in private practice law firms and with corporations as in-house counsel, Ms. Nouri has advised on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, intellectual property portfolio management, public disclosure issues, and SEC reporting and compliance. Ms. Nouri received a J.D. from U.C. College of the Law, San Francisco (formerly U.C. Hastings College of Law) and a Bachelor of Commerce in International Business. She also completed the requirements for a finance specialization from the University of British Columbia.

Ms. Rao has served as our EVP, Chief Strategy and Marketing Officer since November 2025. She previously served as Sr. Vice President, Marketing, Strategy, and Program Management from December 2023 to November 2025, and as Sr. Vice President, Strategy, Program Management, and Advanced Analytics from July 2022 until December 2023, at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Prior to that, Ms. Rao served as Vice President, Strategy, Program Management, and Advanced Analytics from October 2021 until July 2022 and Sr. Director, Strategy, Program Management, and Advanced Analytics from November 2020 until October 2021, among other leadership positions after having started her career at Edwards Life Sciences in July 2007. Ms. Rao received a B.S. in Biomedical Engineering from University of Southern California.

Mr. Templin has over 15 years of experience in clinical research, engineering, and market development, primarily within the medical device industry. Most recently, he served as the VP of Clinical Research, Engineering, and Therapy Development for CardioKinetix. Prior to CardioKinetix, Mr. Templin was the Global Clinical Program Director for Abbott Vascular. He also led the landmark vulnerable plaque natural history study, PROSPECT. Prior to that role, Mr. Templin held engineering roles with GE Aircraft Engines and Guidant, and then clinical positions with Guidant (that was later acquired by Abbott). Mr. Templin holds a B.S. in Mechanical Engineering and minor in Economics from Rose-Hulman Institute of Technology and an MBA from Duke.